Kyowa Hakko Kirin Licenses Anti-LIGHT MAB To Sanofi-Aventis

TOKYO - Kyowa Hakko Kirin signed a licensing agreement with Sanofi-Aventis for worldwide co-development and marketing rights, excluding Japan and Asia, for Kyowa's anti-LIGHT fully humanized monoclonal antibody, the company said May 14